Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue And Provides Corporate Updates; Sees Q4 Revenue $69M-$71M Vs $68.27M Est.; FY23 Revenue $178M-$180M Vs $185.4M Est.; LIVMARLI Net Products Sales Of $141M-143M Expected For 2023
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced preliminary unaudited 2023 net revenue and provided corporate updates. The company expects Q4 revenue of $69M-$71M, slightly above the $68.27M estimate, and FY23 revenue of $178M-$180M, below the $185.4M estimate. LIVMARLI net product sales are projected to be $141M-$143M for 2023, an 89% increase from 2022. Mirum acquired CHOLBAM and CHENODAL, expanded LIVMARLI's US label, and grew its international business. The company is fully financed with a strong balance sheet and announced Eric Bjerkholt as CFO. Mirum anticipates continued revenue growth in 2024, with key milestones including FDA PDUFA date for LIVMARLI, NDA submission for CHENODAL, and interim analyses for volixibat studies.
January 08, 2024 | 1:58 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mirum Pharmaceuticals expects Q4 2023 revenue to slightly exceed estimates, but FY23 revenue to fall short. LIVMARLI sales show strong growth, and the company is positioned for further expansion with a robust pipeline and new CFO.
While Q4 revenue is above estimates, the FY23 revenue miss may temper investor enthusiasm. However, the strong growth in LIVMARLI sales and positive corporate developments could maintain investor confidence in the company's growth trajectory.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100